Targeting Homologous Recombination Repair in Cancer - DNA Repair in Cancer Therapy - page 149

ATM- and KAP-1 dependent pathway. Nat Cell Biol 2006;8(8):
870 e 6.
86. Zha S, Guo C, Boboila C, et al. ATM damage response and XLF
repair factor are functionally redundant in joining DNA breaks.
Nature 2011;469(7329):250 e 4.
87. Helmink BA, Tubbs AT, Dorsett Y, et al. H2AX prevents CtIP-
mediated DNA end resection and aberrant repair in G1-phase
lymphocytes. Nature 2011;469(7329):245 e 9.
88. Bouwman P, Aly A, Escandell JM, et al. 53BP1 loss rescues
BRCA1 deficiency and is associated with triple-negative and
BRCA-mutated breast cancers. Nat Struct Mol Biol 2010;17(6):
688 e 95.
89. Bunting SF, Callen E, Wong N, et al. 53BP1 inhibits homologous
recombination in Brca1-deficient cells by blocking resection of
DNA breaks. Cell 2010;141(2):243 e 54.
90. Beucher A, Birraux J, Tchouandong L, et al. ATM and Artemis
promote homologous recombination of radiation-induced DNA
double-strand breaks in G2. EMBO J 2009;28(21):3413 e 27.
91. Helleday T, Lo J, van Gent DC, Engelward BP. DNA double-
strand break repair: from mechanistic understanding to cancer
treatment. DNA Repair (Amst) 2007;6(7):923 e 35.
92. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA.
DNA repair pathways as targets for cancer therapy. Nat Rev
Cancer 2008;8(3):193 e 204.
93. Petermann E, Orta ML, Issaeva N, Schultz N, Helleday T.
Hydroxyurea-stalled replication forks become progressively
inactivated and require two different RAD51-mediated pathways
for restart and repair. Mol Cell 2010;37(4):492 e 502.
94. Lomonosov M, Anand S, Sangrithi M, Davies R,
Venkitaraman AR. Stabilization of stalled DNA replication forks
by the BRCA2 breast cancer susceptibility protein. Genes Dev
2003;17(24):3017 e 22.
95. Wray J, Liu J, Nickoloff JA, Shen Z. Distinct RAD51 associations
with RAD52 and BCCIP in response to DNA damage and
replication stress. Cancer Res 2008;68(8):2699 e 707.
96. Osborn AJ, Elledge SJ, Zou L. Checking on the fork: the DNA-
replication stress-response pathway. Trends Cell Biol 2002;12(11):
509 e 16.
97. Hinz JM. Role of homologous recombination in DNA interstrand
crosslink repair. Environ Mol Mutagen 2010;51(6):582 e 603.
98. Kee Y, D'Andrea AD. Expanded roles of the Fanconi anemia
pathway in preserving genomic stability. Genes Dev 2010;24(16):
1680 e 94.
99. Kennedy RD, D'Andrea AD. The Fanconi Anemia/BRCA
pathway: new faces in the crowd. Genes Dev 2005;19(24):2925 e 40.
100. Wang W. Emergence of a DNA-damage response network
consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet
2007;8(10):735 e 48.
101. Smogorzewska A, Matsuoka S, Vinciguerra P, et al. Identification
of the FANCI protein, a monoubiquitinated FANCD2 paralog
required for DNA repair. Cell 2007;129(2):289 e 301.
102. Kim Y, Lach FP, Desetty R, Hanenberg H, Auerbach AD,
Smogorzewska A. Mutations of the SLX4 gene in Fanconi anemia.
Nat Genet 2010;43(2):142 e 6.
103. Niedernhofer LJ, Lalai AS, Hoeijmakers JH. Fanconi anemia
(cross)linked to DNA repair. Cell 2005;123(7):1191 e 8.
104. Digweed M, Rothe S, Demuth I, et al. Attenuation of the forma-
tion of DNA-repair foci containing RAD51 in Fanconi anaemia.
Carcinogenesis 2002;23(7):1121 e 6.
105. Garcia-Higuera I, Taniguchi T, Ganesan S, et al. Interaction of the
Fanconi anemia proteins and BRCA1 in a common pathway.
Mol Cell 2001;7(2):249 e 62.
106. Wang X, Andreassen PR, D'Andrea AD. Functional interaction of
monoubiquitinated FANCD2 and BRCA2/FANCD1 in chro-
matin. Mol Cell Biol 2004;24(13):5850 e 62.

107. Vaz F, Hanenberg H, Schuster B, et al. Mutation of the RAD51C
gene in a Fanconi anemia-like disorder. Nat Genet 2010;42(5):
406 e 9.
108. Garcia-Higuera I, Taniguchi T, Ganesan S, et al. Interaction of the
Fanconi anemia proteins and BRCA1 in a common pathway.
Molecular Cell 2001;7(2):249 e 62.
109. Litman R, Peng M, Jin Z, et al. BACH1 is critical for homologous
recombination and appears to be the Fanconi anemia gene
product FANCJ. Cancer Cell 2005;8(3):255 e 65.
110. Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of
BRCA2 in Fanconi anemia [see comment]. Science 2002;297(5581):
606 e 9.
111. Hirano S, Yamamoto K, Ishiai M, et al. Functional relationships of
FANCC to homologous recombination, translesion synthesis, and
BLM. EMBO J 2005;24(2):418 e 27.
112. Wilson JB, Blom E, Cunningham R, Xiao Y, Kupfer GM, Jones NJ.
Several tetratricopeptide repeat (TPR) motifs of FANCG are
required for assembly of the BRCA2/D1-D2-G-X3 complex,
FANCD2 monoubiquitylation and phleomycin resistance. Mutat
Res 2010;689:12 e 20.
113. Wilson JB, Yamamoto K, Marriott AS, et al. FANCG promotes
formation of a newly identified protein complex containing
BRCA2, FANCD2 and XRCC3. Oncogene 2008;27(26):3641 e 52.
114. Shen X, Do H, Li Y, et al. Recruitment of fanconi anemia and
breast cancer proteins to DNA damage sites is differentially
governed by replication. Mol Cell 2009;35(5):716 e 23.
115. Bagby GC, Alter BP. Fanconi anemia. Semin Hematol 2006;43(3):
147 e 56.
116. Matsushita N, Kitao H, Ishiai M, et al. A FancD2-monoubiquitin
fusion reveals hidden functions of Fanconi anemia core complex
in DNA repair. Mol Cell 2005;19(6):841 e 7.
117. Medhurst AL, Laghmani el H, Steltenpool J, et al. Evidence for
subcomplexes in the Fanconi anemia pathway. Blood 2006;108(6):
2072 e 80.
118. Willers H, Kachnic LA, Luo CM, et al. Biomarkers and mecha-
nisms of FANCD2 function. J Biomed Biotechnol 2008;2008:821 e 9.
119. Gordon SM, Alon N, Buchwald MFANCC. FANCE, and FANCD2
form a ternary complex essential to the integrity of the Fanconi
anemia DNA damage response pathway. J Biol Chem 2005;

280(43):36118 e 25.
120. Howlett NG, Harney JA, Rego MA, Kolling FWT, Glover TW.
Functional interaction between the Fanconi Anemia D2 protein
and proliferating cell nuclear antigen (PCNA) via a conserved
putative PCNA interaction motif.

J Biol Chem 2009;284(42):

28935 e 42.
121. Kachnic LA, Li L, Fournier L, Willers H. Fanconi anemia pathway
heterogeneity revealed by cisplatin and oxaliplatin treatments.
Cancer Lett ; 292(1): 73-9.
122. Zhi G, Chen X, Newcomb W, Brown J, Semmes OJ, Kupfer GM.
Purification of FANCD2 sub-complexes. Br J Haematol 2010;
150(1):88 e 92.
123. Bartek J, Lukas J, Bartkova J. DNA damage response as an anti-
cancer barrier: damage threshold and the concept of "conditional
haploinsufficiency". Cell Cycle 2007;6(19):2344 e 7.
124. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced
DNA damage model for cancer development. Science 2008;

319(5868):1352 e 5.
125. Jackson SP, Bartek J. The DNA-damage response in human
biology and disease. Nature 2009;461(7267):1071 e 8.
126. Moynahan ME, Jasin M. Mitotic homologous recombination
maintains genomic stability and suppresses tumorigenesis. Nat
Rev Mol Cell Biol 2010;11(3):196 e 207.
127. Reliene R, Bishop AJ, Schiestl RH. Involvement of homologous
recombination in carcinogenesis. Adv Genet 2007;58:67 e 87.